TY - CHAP M1 - Book, Section TI - Cell Therapy for Cardiovascular Diseases A1 - Shen, Jia A1 - Henry, Timothy D. A1 - Quyyumi, Arshed A. A2 - Samady, Habib A2 - Fearon, William F. A2 - Yeung, Alan C. A2 - King III, Spencer B. PY - 2017 T2 - Interventional Cardiology, 2e AB - Ischemic heart disease and heart failure continue to be the predominant causes of morbidity and mortality worldwide. Acute myocardial infarction is the most common cause of heart failure and triggers a series of cellular and molecular changes leading to apoptosis, necrosis, hypertrophy of cardiomyocytes, impaired neovascularization, interstitial fibrosis, inflammation, reduced contractility, and pathologic remodeling.1 Despite advances in medical and device therapy, hospitalization rates and mortality for heart failure continue to remain high, with 1 in 5 patients dying within 12 months of diagnosis.2 Medical therapy has centered on the treatment of underlying risk factors and on the initiation of antiplatelet, lipid-lowering, β-adrenergic receptor, and angiotensin antagonist therapy. Interventions designed to facilitate cardiovascular regeneration were not initially pursued because it was assumed that the adult heart is a terminally differentiated postmitotic organ where the number of cardiomyocytes are established at birth, with no potential for regeneration after damage.3 SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - accesscardiology.mhmedical.com/content.aspx?aid=1146607053 ER -